Skip to main content
Business

Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies

MAP Verified Summary — reported by Fortune

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.

This story was scored across MAP’s five-signal verification framework — Context, Presentation, References, Visibility, and Comparison — as part of Media Alert Press’s independent media credibility index. Read the full original story at Fortune →


Discover more from Media Alert Press

Subscribe to get the latest posts sent to your email.

Original Source

This article was syndicated from Fortune. All rights remain with the original publisher.